| 1,083 | 41 | 172 |
| 下载次数 | 被引频次 | 阅读次数 |
非酒精性脂肪肝疾病(non-alcoholic fatty liver disease,NAFLD)是一类组织病理学异常,以弥漫性肝细胞脂肪变性为主要特征的常见慢性肝病。其发病机制目前尚不十分清楚,胰岛素抵抗与脂质代谢异常可能是其发病的中心环节,肿瘤坏死因子、白介素、瘦素、脂联素、抵抗素等多种脂肪细胞因子以及脂肪生成相关转录因子在NAFLD的发生发展中发挥了重要的作用。
Abstract：Non-alcoholic fatty liver disease(NAFLD) is a common chronic liver disease,which represents a spectrum of histopathologic abnormalities and characterized by diffuse fatty degeneration of liver cells.The pathogenesis of NAFLD is not very clear,insulin resistance and lipid metabolism abnormality may be the central link in its pathogenesy.Tumor necrosis factor,interleukins,leptin,adiponectin,resistin and lipogenesis transcription factors play important roles in the occurrence and development of NAFLD.
[1]Marchesini G,Bugianesi E,Forlani G,et al.Nonalcoholicfatty liver,steatohepatitis,and the metabolic syndrome[J].Hepatology,2003,37(4):917-923.
[2]Boschmann M,Engeli S,Moro C,et al.LMNA mutations,skeletal muscle lipid metabolism,and insulin resistance[J].J Clin Endocrinol Metab,2010,95(4):1634-1643.
[3]Polyzos SA,Kountouras J,Zavos C.Nonalcoholic fatty liverdisease:the pathogenetic roles of insulin resistance andadipocytokines[J].Curr Mol Med,2009,9(3):299-314.
[4]陈晓路.非酒精性脂肪肝发病机制研究进展[J].人民军医,2010,53(2):147-148.
[5]Cave M,Deaciuc I,Mendez C,et al.Non-alcoholic fattyliver disease:predisposing factors and the role of nutrition[J].J Nutr Biochem,2007,18(3):184-195.
[6]Bjornsson E,Angulo P.Non-alcoholic fatty liver disease[J].Scand J Gastroentenol,2007,42(9):1023-1130.
[7]李秀丽,王蒙.非酒精性脂肪肝病发病机制的研究进展[J].时珍国医国药,2010,21(10):2647-2648.
[8]郭晓鹤,李贞娟,张彩凤,等.肿瘤坏死因子-α与非酒精性脂肪肝的关系[J].胃肠病学和肝病学杂志,2011,20(7):655-658.
[9]Guha IN,Parkes J,Roderick P,et al.Noninvasive markersof fibrosis in nonalcoholic fatty liver disease:Validating theEuropean Liver Fibrosis Panel and exploring simplemark-ers[J].Hepatology,2008,47(2):455-460.
[10]Fan XF,Deng YQ,Ye L,et al.Effect of Xuezhikang Cap-sule on serum tumor necrosis factor-αand interleukin-6in patients with nonalcoholic fatty liver disease and hy-perlipidemia[J].Chin J Integr Med,2010,16(2):119-123.
[11]Harano Y,Yasui K,Toyama T,et al.Fenofibrate,a per-oxisome proliferator-activated receptor alpha agonist,re-duces hepatic steatosis and lipid peroxidation in fatty liverShionogimice with hereditary fatty liver[J].Liver Int,2006,26(5):613-620.
[12]Duseja A,Thumburu KK,Das A,et al.Insulin tolerancetest is comparable to homeostasis model assessment for in-sulin resistance in patients with nonalcoholic fatty liverdisease[J].Indian J Gastroenterol,2007,26(4):170-173.
[13]程勇,言红健,孟杰,等.非酒精性脂肪性肝病患者肝损伤程度与IL-18、IL-8含量的相关性[J].中国老年学杂志,2011,31(9):1528-1529.
[14]Ahmed MH,Saad RA,Osman MM.Ezetimibe:effectiveand safe treatment for dyslipidaemia associated with non-alcoholic fatty liver disease.Response to:Toth PP,David-son MH:simvastatin and ezetimibe:combination therapy forthe management of dyslipidaemia[J].Expert Opin Pharma-cother,2006,5(4):487-488.
[15]Membrez M,Ammon-Zufferey C,Philippe D,et al.Inter-leukin-18 protein level is upregulated in adipose tissue ofobese mice[J].Obesity,2009,17(2):393-395.
[16]Zhang X,Yeung DC,Karpisek M,et al.Serum FGF-21levels are increased in obesity and are independently as-sociated with the metabolic syndrome in humans[J].Dia-betes,2008,57(5):1246-1253.
[17]Badman MK,Pissios P,Kennedy AR,et al.Hepatic fi-boblastgrowth factor 21 is regulated by PPAR-alpha andis a key mdeiator of hepatic lipid matabolism in ketoticstates[J].Cell Metab,2007,5(6):426-437.
[18]王乐,张霞.非酒精性脂肪肝分子机制的研究进展[J].现代预防医学,2010,37(11):2027-2030.
[19]巩萱.脂联素及其受体在大鼠非酒精性脂肪性肝病发病中的作用研究[D].厦门:厦门大学附属中山医院,2010:23.
[20]Asano T,Watanabe K,Kubota N,et al.Adiponectinknock-out mice on high fat diet develop fibrosing steato-hepatitis[J].J Gastroenterol Hepatol,2009,24(10):1669-1676.
[21]Savvidou S,Hytiroglou P,Orfanou-Koumerkeridou H,etal.Low serum adiponectin levels are predictive of ad-vanced hepatic fibrosis in patients with NAFLD[J].J Clin-ical Gastroenterol,2009,43(8):765-772.
[22]Ding X,Saxena NK,Lin S,et al.The roles of leptin andadiponectin:a novel paradigm in adipocytokine regulationof liver fibrosis and stellate cell biology[J].Am J Pathol,2005,166(6):1655-1669.
[23]Steppan CM,Bailey ST,Bhat S,et al.The hormone re-sistin links obesity to diabetes[J].Nature,2001,409(6818):307-312.
[24]赵和平,杨文慧,段晓燕,等.动态观察非酒精性脂肪肝大鼠肝脏抵抗素的表现[J].国际内科学杂志,2007,34(11):628-631.
[25]Seo JA,Kim NH,Park SY,et al.Serum retinol-bindingprotein 4 levels are elevated in non-alcoholic fatty liverdisease[J].Clin Endocrinol,2008,68(4):555-560.
[26]董闪闪,张力辉.视黄醇结合蛋白4与非酒精性脂肪性肝病关系的研究进展[J].临床荟萃.2009,24(6):547-549.
[27]Detivaud L,Nemeth E,boudjema K,et al.Hepcidin levelsin humans are correlated with hepatic iron stores,hemoglobin levels,and hepatic function[J].Blood,2005,106(2):746-748.
[28]Barisani D,Pelucchi S,Mariani R,et al.Hepcidin andiron-related gene expression in subjects with DysmetabolicHepatic iron Overload[J].J Hepatol,2008,49(1):123-133.
[29]高爱滨,肖谦.PPARα与非酒精性脂肪肝[J].国际消化病杂志,2007,27(1):19-21.
[30]Schroeder F,Petrescu AD,Huang H,et al.Role of fattyacid binding proteins and long chain fatty acids in modu-lating nuclear receptors and gene transcription[J].Lipids,2008,43(1):1-17.
[31]Ascencio C,Torres N,Isoard-Acosta F,et al.Soy proteinaffects serum insulin and hepatic SREBP-1MRNA andreduces fatty liver in rats[J].J Nutr,2004,134(3):522-
基本信息:
中图分类号:R575.5
引用信息:
[1]常珊珊,徐济良.非酒精性脂肪肝发病相关因子的机制研究新进展[J].南通大学学报(医学版),2013,33(01):56-60.
基金信息:
科技部“十一五”国家科技支撑计划子课题(2006DAI06A20-02);; 南通大学研究生科技创新计划项目(YKC11006);; 江苏省优势学科建设工程资助项目